These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2558839)

  • 1. Debut of a somatostatin analog: octreotide in review.
    Zindel LR
    Conn Med; 1989 Dec; 53(12):741-4. PubMed ID: 2558839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide, a new somatostatin analogue.
    Katz MD; Erstad BL
    Clin Pharm; 1989 Apr; 8(4):255-73. PubMed ID: 2653711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
    Williams G; Anderson JV; Williams SJ; Bloom SR
    Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Somatostatin analog (octreotide) in clinical use: current and potential indications].
    Meier R; Dierdorf R; Gyr K
    Schweiz Med Wochenschr; 1992 Jun; 122(25):957-68. PubMed ID: 1621078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
    Ben Yosef R; Glaser B; Catane R
    Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical use of octreotide (Sandostatin) in endocrinology].
    Prelević GM
    Med Pregl; 1993; 46(9-10):343-8. PubMed ID: 7997211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
    Cho KJ; Vinik AI
    Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
    Flückiger A; Schlup P
    Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
    Stöckmann F; Creutzfeldt W
    Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacodynamic analysis of octreotide in acromegalic patients.
    Comets E; Mentré F; Grass P; Kawai R; Marbach P; Vonderscher J
    Clin Pharmacol Ther; 2003 Jan; 73(1):95-106. PubMed ID: 12545148
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management.
    Redfern JS; Fortuner WJ
    Am J Gastroenterol; 1995 Jul; 90(7):1042-52. PubMed ID: 7611194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging indications for octreotide therapy, Part 1.
    Mosdell KW; Visconti JA
    Am J Hosp Pharm; 1994 May; 51(9):1184-92. PubMed ID: 8042637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metastasizing pancreatic vipoma. Its diagnosis and therapy with the somatostatin analog octreotide].
    Scheffold N; Arnold R; Cyran J
    Dtsch Med Wochenschr; 1995 Oct; 120(43):1463-7. PubMed ID: 7588006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
    George SR; Hegele RA; Burrow GN
    Clin Invest Med; 1987 Jul; 10(4):309-15. PubMed ID: 2888554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide inhibition of flushing and colonic motor dysfunction in carcinoid syndrome.
    Saslow SB; O'Brien MD; Camilleri M; von der Ohe M; Homburger HA; Klee GG; Pitot HC; Rubin J
    Am J Gastroenterol; 1997 Dec; 92(12):2250-6. PubMed ID: 9399764
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pasireotide--a somatostatin analog for the potential treatment of acromegaly, neuroendocrine tumors and Cushing's disease.
    Ben-Shlomo A; Melmed S
    IDrugs; 2007 Dec; 10(12):885-95. PubMed ID: 18041687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic dose-extension of octreotide LAR: the importance of individual tailoring of treatment in patients with acromegaly.
    Turner HE; Thornton-Jones VA; Wass JA
    Clin Endocrinol (Oxf); 2004 Aug; 61(2):224-31. PubMed ID: 15272918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acromegaly with octreotide: effectiveness and tolerability of its pulsatile administration by portable pump.
    Giusti M; Cuttica CM; Cariola G; Valenti S; Sessarego P; Giordano G
    Recenti Prog Med; 1995 May; 86(5):189-94. PubMed ID: 7604174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F; Magony S; Julesz J
    Orv Hetil; 2002 May; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.